Health Condition 1: null- immediate Post renal trasnplant recipients Health Condition 2: Z940- Kidney transplant status
Conditions
Interventions
Intervention1: valganciclovir: Tablet.valganciclovir
900mg per oral
once a day- thrice weekly
1)Duration of therapy 3 months for the following
a)Donor seropostive and
recipient seropositive
Sponsors
Postgraduate Institute of Medical Education and research
Eligibility
Inclusion criteria
Inclusion criteria: Patients undergoing renal transplant during period of January 2018 to December 2018 with 1) >= 16 years of age 2) Adequate hematological and renal function(defined as a creatinine 3) clearance >10 mL/min by day 10 posttransplant) 4) CMV Donor/Recipient serostatus D+/R+, D+/Râ?? and D-/R+
Exclusion criteria
Exclusion criteria: 1.) Patients refusing consent. 2.) Significant gastrointestinal disease that could affect drug absorption. 3.) suspected CMV disease at enrolment. 4.) HIV, hepatitis B or hepatitis C 5.) use of anti-CMV therapy within 30 days prior to study 6.) multiple organ transplantation 7.) allergies or previous adverse reactions to ganciclovir or valganciclovir 8.) severe uncontrolled diarrhea or evidence of malabsorption 9.) serious psychiatric or medical disorder 10.) male with a pregnant partner. 11.) liver function tests >3 times the upper level of normal (ULN).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytomegalovirus incidenceTimepoint: one, three and six months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Adverse effects, acute rejection, opportunistic infection, eGFR. 2) To screen for other immunomodulatory viruses such as hepatitis B,hepatitis C and BK virus when where necessary. Timepoint: one,three and six months | — |
Countries
India
Contacts
Public ContactDr Rudreshwar Prabakaran
Postgraduate Institute of Medical Education and Research
Outcome results
None listed